Cargando…
Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict susceptible sites of metabolism and structural alerts...
Autores principales: | Alsibaee, Aishah M., Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali S., Kadi, Adnan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220799/ https://www.ncbi.nlm.nih.gov/pubmed/37241965 http://dx.doi.org/10.3390/molecules28104225 |
Ejemplares similares
-
Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study
por: Alsibaee, Aishah M., et al.
Publicado: (2023) -
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation
por: Attwa, Mohamed W., et al.
Publicado: (2018) -
Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
por: Abdelhameed, Ali S., et al.
Publicado: (2020) -
Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2019) -
Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
por: Attwa, Mohamed W., et al.
Publicado: (2018)